Document And Entity Information - USD ($)	12 Months Ended
Document And Entity Information - USD ($)	Dec. 31, 2015	Mar. 01, 2016	Jun. 30, 2015
Document Information [Line Items]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2015
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	FY
Entity Registrant Name	TG THERAPEUTICS, INC.
Entity Central Index Key	0001001316
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Accelerated Filer
Entity Public Float			$ 570,132,000
Trading Symbol	TGTX
Entity Common Stock, Shares Outstanding		54,095,110

Consolidated Balance Sheets - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Current assets:
Cash and cash equivalents	$ 55,061,329	$ 55,713,784
Short-term investment securities	22,166,512	23,062,034
Interest receivable	186,021	85,516
Prepaid research and development	9,151,142	6,179,743
Other current assets	308,327	173,952
Total current assets	86,873,331	85,215,029
Restricted cash	579,143	575,012
Long-term investment securities	25,003,032	0
Property, plant and equipment, net	47,122	20,357
Goodwill	799,391	799,391
Other assets	171,182	137,101
Total assets	113,473,201	86,746,890
Current liabilities:
Accounts payable and accrued expenses	9,346,068	3,991,625
Accrued compensation	818,472	702,000
Current portion of deferred revenue	152,381	152,381
Notes payable	211,549	275,190
Total current liabilities	10,528,470	5,121,196
Deferred revenue, net of current portion	1,371,429	1,523,810
Total liabilities	$ 11,899,899	$ 6,645,006
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.001 par value per share (10,000,000 shares authorized, none issued and outstanding as of December 31, 2015 and 2014)	$ 0	$ 0
Common stock, $0.001 par value per share (150,000,000 shares authorized, 54,095,110 and 44,974,248 shares issued, 54,053,801 and 44,932,939 shares outstanding at December 31, 2015 and 2014, respectively)	54,095	44,974
Contingently issuable shares	6	6
Additional paid-in capital	259,887,464	175,476,521
Treasury stock, at cost, 41,309 shares at December 31, 2015 and 2014	(234,337)	(234,337)
Accumulated deficit	(158,133,926)	(95,185,280)
Total stockholders’ equity	101,573,302	80,101,884
Total liabilities and stockholders’ equity	$ 113,473,201	$ 86,746,890

Consolidated Balance Sheets [Parenthetical] - $ / shares	Dec. 31, 2015	Dec. 31, 2014
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	150,000,000	150,000,000
Common stock, shares issued	54,095,110	44,974,248
Common stock, shares outstanding	54,053,801	44,932,939
Treasury stock, shares	41,309	41,309

Consolidated Statements of Operations - USD ($)	12 Months Ended
Consolidated Statements of Operations - USD ($)	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
License revenue	$ 152,381	$ 152,381	$ 152,381
Research and development:
Noncash stock expense associated with in-licensing agreements	0	5,350,094	0
Noncash compensation	4,261,406	8,731,566	1,041,519
Other research and development	43,445,817	26,004,687	12,621,161
Total research and development	47,707,223	40,086,347	13,662,680
General and administrative:
Noncash compensation	11,435,686	12,373,726	4,161,629
Other general and administrative	4,189,488	3,413,400	2,496,461
Total general and administrative	15,625,174	15,787,126	6,658,090
Impairment of in-process research and development	0	0	2,797,600
Total costs and expenses	63,332,397	55,873,473	23,118,370
Operating loss	(63,180,016)	(55,721,092)	(22,965,989)
Other (income) expense:
Interest income	(174,653)	(55,049)	(30,822)
Other income	0	(95,427)	(108,894)
Interest expense	972,736	930,701	952,888
Change in fair value of notes payable	(1,029,453)	(720,040)	(3,300,951)
Total other (income) expense, net	(231,370)	60,185	(2,487,779)
Net loss	$ (62,948,646)	$ (55,781,277)	$ (20,478,210)
Basic and diluted net loss per common share (in dollars per share)	$ (1.38)	$ (1.64)	$ (0.81)
Weighted average shares used in computing basic and diluted net loss per common share (in shares)	45,646,414	34,068,926	25,413,964

Consolidated Statements of Equity - USD ($)	Total	Common Stock [Member]	Contingently Issuable Shares [Member]	Additional Paid-in Capital [Member]	Treasury Stock [Member]	Accumulated Deficit [Member]
Balance at Dec. 31, 2012	$ 15,550,301	$ 25,821		$ 34,534,805	$ (84,538)	$ (18,925,793)
Balance (in shares) at Dec. 31, 2012		25,820,738	6		13,526
Issuance of common stock in connection with exercise of warrants	2,280,773	$ 1,013		2,279,760
Issuance of common stock in connection with exercise of warrants (in shares)		1,013,009
Issuance of common stock in connection with cashless exercise of warrants	(1)	$ 3		(4)
Issuance of common stock in connection with cashless exercise of warrants (in shares)		3,024
Issuance of restricted stock	0	$ 944		(944)
Issuance of restricted stock (in shares)		944,464
Issuance of common stock in At-the-Market offering (net of offering costs of $1,310,591)	37,648,280	$ 6,555		37,641,725
Issuance of common stock in At-the-Market offering (net of offering costs of $1,310,591) (in shares)		6,555,000
Compensation in respect of restricted stock granted to employees, directors and consultants	5,203,148			5,203,148
Surrender of common stock for tax withholding	(149,799)				$ (149,799)
Surrender of common stock for tax withholding (in shares)					27,783
Net loss	(20,478,210)					(20,478,210)
Balance at Dec. 31, 2013	40,054,492	$ 34,336		79,658,490	$ (234,337)	(39,404,003)
Balance (in shares) at Dec. 31, 2013		34,336,235	6		41,309
Issuance of common stock in connection with exercise of warrants	3,556,624	$ 1,561		3,555,063
Issuance of common stock in connection with exercise of warrants (in shares)		1,560,826
Issuance of common stock in connection with exercise of options	202,400	$ 46		202,354
Issuance of common stock in connection with exercise of options in shares (in shares)		46,000
Issuance of restricted stock	0	$ 983		(983)
Issuance of restricted stock (in shares)		982,793
Forfeiture of restricted stock	0	$ (1)		1
Forfeiture of restricted stock (in shares)		(1,000)
Issuance of common stock in At-the-Market offering (net of offering costs of $1,310,591)	16,791,408	$ 2,703		16,788,705
Issuance of common stock in At-the-Market offering (net of offering costs of $1,310,591) (in shares)		2,702,809
Compensation in respect of restricted stock granted to employees, directors and consultants	21,105,292			21,105,292
Issuance of common stock in At the Market offering	48,822,852	$ 4,850		48,818,002
Issuance of common stock in At the Market offering (in shares)		4,850,055
Common stock issued in connection with in-licensing agreements	5,350,093	$ 496		5,349,597
Common stock issued in connection with in-licensing agreements (in shares)		496,530
Net loss	(55,781,277)					(55,781,277)
Balance at Dec. 31, 2014	80,101,884	$ 44,974		175,476,521	$ (234,337)	(95,185,280)
Balance (in shares) at Dec. 31, 2014		44,974,248	6		41,309
Issuance of common stock in connection with exercise of warrants	1,067,339	$ 2,946		1,064,393
Issuance of common stock in connection with exercise of warrants (in shares)		2,946,703
Issuance of common stock in connection with cashless exercise of warrants	0	$ 3		(3)
Issuance of common stock in connection with cashless exercise of warrants (in shares)		2,915
Issuance of common stock in connection with conversion of notes payable	6,925	$ 1		6,924
Issuance of common stock in connection with conversion of notes payable (in shares)		522
Issuance of restricted stock	0	$ 1,993		(1,993)
Issuance of restricted stock (in shares)		1,992,535
Forfeiture of restricted stock	0	$ (31)		31
Forfeiture of restricted stock (in shares)		(31,166)
Issuance of common stock to related party for cash (See Note 9)	750,005	$ 115		749,890
Issuance of common stock to related party for cash (See Note 9) (in shares)		114,855
Compensation in respect of restricted stock granted to employees, directors and consultants	15,697,092			15,697,092
Issuance of common stock in At the Market offering	66,898,703	$ 4,094		66,894,609
Issuance of common stock in At the Market offering (in shares)		4,094,498
Net loss	(62,948,646)					(62,948,646)
Balance at Dec. 31, 2015	$ 101,573,302	$ 54,095		$ 259,887,464	$ (234,337)	$ (158,133,926)
Balance (in shares) at Dec. 31, 2015		54,095,110	6		41,309

Condensed Consolidated Statements of Equity [Parenthetical] - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Payments of Stock Issuance Costs	$ 1,310,591	$ 1,101,572
Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs		$ 1,344,440	$ 2,664,970

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
Consolidated Statements of Cash Flows - USD ($)	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
CASH FLOWS FROM OPERATING ACTIVITIES
Consolidated net loss	$ (62,948,646)	$ (55,781,277)	$ (20,478,210)
Adjustments to reconcile consolidated net loss to net cash used in operating activities:
Gain on settlement of notes payable	0	(95,427)	0
Noncash stock compensation expense	15,697,092	21,105,292	5,203,148
Noncash stock expense associated with in-licensing agreements	0	5,350,094	0
Impairment of in-process research and development	0	0	2,797,600
Depreciation	15,452	3,931	1,127
Amortization of premium on investment securities	536,142	193,581	975
Change in fair value of notes payable	(56,717)	210,661	(2,414,569)
Changes in assets and liabilities:
Increase in restricted cash	(4,131)	(575,012)	0
(Increase) decrease in other current assets	(3,105,771)	(4,563,067)	229,258
Increase in accrued interest receivable	(100,505)	(58,347)	(27,169)
Increase in other assets	(41,722)	0	0
Increase (decrease) in accounts payable and accrued expenses	5,470,915	(603,377)	4,034,605
Increase (decrease) in interest payable	0	(94,590)	66,506
Decrease in deferred revenue	(152,381)	(152,381)	(152,381)
Net cash used in operating activities	(44,690,272)	(35,059,919)	(10,739,110)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchases of property, plant and equipment	(42,217)	(18,570)	(5,681)
Investment in held-to-maturity securities	(48,993,652)	(18,336,719)	(4,919,871)
Proceeds from maturity of short-term securities	24,350,000	0	0
Net cash used in investing activities	(24,685,869)	(18,355,289)	(4,925,552)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from the exercise of warrants	1,067,339	3,556,624	2,280,773
Proceeds from the exercise of options	0	202,400	0
Payment of notes payable	0	(677,778)	0
Proceeds from sale of common stock, net	67,760,517	65,614,260	37,648,280
Deferred financing costs paid	(104,170)	(51,980)	(85,121)
Purchase of treasury stock	0	0	(149,799)
Net cash provided by financing activities	68,723,686	68,643,526	39,694,133
NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS	(652,455)	15,228,318	24,029,471
Cash and cash equivalents at beginning of year	55,713,784	40,485,466	16,455,995
CASH AND CASH EQUIVALENTS AT END OF YEAR	55,061,329	55,713,784	40,485,466
NONCASH TRANSACTIONS
Reclassification of deferred financing costs to additional paid-in capital	(111,810)	0	0
Conversion of convertible notes payable to common stock	$ 6,924	$ 0	$ 0

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

12 Months Ended

Dec. 31, 2015

Accounting Policies [Abstract]

Significant Accounting Policies [Text Block]

NOTE 1 – ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

DESCRIPTION OF BUSINESS

We are a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Currently, the Company is developing two therapies targeting hematologic malignancies. TG-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes. We are also developing TGR-1202, an orally available PI3K delta inhibitor. The delta isoform of PI3K is strongly expressed in cells of hematopoietic origin and is believed to be important in the proliferation and survival of B-lymphocytes. Both TG-1101 and TGR-1202 are in clinical development for patients with hematologic malignancies. The Company also has pre-clinical programs seeking to develop IRAK4 (interleukin-1 receptor-associated kinase 4) inhibitors and anti-PD-L1 and anti-GITR antibodies.

We also actively evaluate complementary products, technologies and companies for in-licensing, partnership, acquisition and/or investment opportunities. To date, we have not received approval for the sale of any of our drug candidates in any market and, therefore, have not generated any product sales from our drug candidates.

LIQUIDITY AND CAPITAL RESOURCES

We have incurred operating losses since our inception, and expect to continue to incur operating losses for the foreseeable future and may never become profitable. As of December 31, 2015, we have an accumulated deficit of $158.1 million.

Our major sources of cash have been proceeds from the private placement and public offering of equity securities. We have not yet commercialized any of our drug candidates and cannot be sure if we will ever be able to do so. Even if we commercialize one or more of our drug candidates, we may not become profitable. Our ability to achieve profitability depends on many factors, including our ability to obtain regulatory approval for our drug candidates; successfully complete any post-approval regulatory obligations; and successfully commercialize our drug candidates alone or in partnership. We may continue to incur substantial operating losses even if we begin to generate revenues from our drug candidates.

As of December 31, 2015, we had $102.4 million in cash and cash equivalents, investment securities, and interest receivable. We currently anticipate that our cash and cash equivalents to be sufficient to fund our anticipated operating cash requirements for more than 24 months from December 31, 2015. The actual amount of cash that we will need to operate is subject to many factors, including, but not limited to, the timing, design and conduct of clinical trials for our drug candidates. We are dependent upon significant future financing to provide the cash necessary to execute our current operations, including the commercialization of any of our drug candidates.

Our common stock is quoted on the Nasdaq Capital Market and trades under the symbol “TGTX.”

RECENTLY ISSUED ACCOUNTING STANDARDS

In May 2014, the Financial Accounting Standards Board (“FASB”) issued an update to Accounting Standards Codification (“ASC”) 606, Revenue from Contracts with Customers. This update to ASC 606 provides a five-step process to determine when and how revenue is recognized. The core principle of the guidance is that a Company should recognize revenue upon transfer of promised goods or services to customers in an amount that reflects the expected consideration to be received in exchange for those goods or services. This update to ASC 606 will also result in enhanced disclosures about revenue, providing guidance for transactions that were not previously addressed comprehensively, and improving guidance for multiple-element arrangements. This update to ASC 606 is effective for us beginning in fiscal 2018. We are currently evaluating the impact of this update on our consolidated financial statements.

In August 2014, the FASB issued Accounting Standards Update 2014-15, Presentation of Financial Statements—Going Concern, which requires management of an entity to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date that the financial statements are issued or available to be issued. This update will become effective beginning January 1, 2017, with early adoption permitted. The provisions of this standard are not expected to significantly impact the Company.

In November 2015, the FASB issued Accounting Standards Update 2015-17, Balance Sheet Classification of Deferred Taxes. This update requires that deferred tax liabilities and assets be classified as noncurrent in a classified statement of financial position. The amendments in this update apply to all entities that present a classified statement of financial position. This update will become effective for public business entities for annual periods beginning after December 15, 2016, and interim periods within those annual periods. The provisions of this standard are not expected to significantly impact the Company.

In February 2016, the FASB issued ASU No. 2016-02, “Leases (Topic 842),” which requires lessees to recognize assets and liabilities for the rights and obligations created by most leases on their balance sheet. The guidance is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Early application is permitted. ASU 2016-02 requires modified retrospective adoption for all leases existing at, or entered into after, the date of initial application, with an option to use certain transition relief. The Company is currently evaluating the impact the standard may have on its consolidated financial statements and related disclosures.

Other pronouncements issued by the FASB or other authoritative accounting standards group with future effective dates are either not applicable or not significant to our consolidated financial statements.

USE OF ESTIMATES

The preparation of financial statements in conformity with U.S. generally accepted accounting principles (“GAAP”) requires management to make estimates and judgments that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the applicable reporting period. Actual results could differ from those estimates. Such differences could be material to the financial statements.

CASH AND CASH EQUIVALENTS

We treat liquid investments with original maturities of less than three months when purchased as cash and cash equivalents.

RESTRICTED CASH

We record cash pledged or held in trust as restricted cash. As of December 31, 2015, we have approximately $0.6 million of restricted cash pledged to secure a line of credit as a security deposit for a Desk Agreement (see Note 9).

INVESTMENT SECURITIES

Investment securities at December 31, 2015 and 2014 consist of short-term and long-term government securities. We classify these securities as held-to-maturity. Held-to-maturity securities are those securities in which we have the ability and intent to hold the security until maturity. Held-to-maturity securities are recorded at amortized cost, adjusted for the amortization or accretion of premiums or discounts. Premiums and discounts are amortized or accreted over the life of the related held-to-maturity security as an adjustment to yield using the effective interest method.

A decline in the market value of any investment security below cost, that is deemed to be other than temporary, results in a reduction in the carrying amount to fair value. The impairment is charged to operations and a new cost basis for the security is established. Other-than-temporary impairment charges are included in interest and other income (expense), net. Unrealized gains, if determined to be temporary, are included in accumulated other comprehensive income in equity. Dividend and interest income are recognized when earned.

CREDIT RISK

Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents, short-term investments and long-term investments. The Company maintains its cash and cash equivalents with high-credit quality financial institutions. At times, such amounts may exceed federally-insured limits.

REVENUE RECOGNITION

We recognize license revenue in accordance with the revenue recognition guidance of the FASB Accounting Standards Codification, or Codification. We analyze each element of our licensing agreement to determine the appropriate revenue recognition. The terms of the license agreement may include payments to us of non-refundable up-front license fees, milestone payments if specified objectives are achieved, and/or royalties on product sales. We recognize revenue from upfront payments over the period of significant involvement under the related agreements unless the fee is in exchange for products delivered or services rendered that represent the culmination of a separate earnings process and no further performance obligation exists under the contract. We recognize milestone payments as revenue upon the achievement of specified milestones only if (1) the milestone payment is non-refundable, (2) substantive effort is involved in achieving the milestone, (3) the amount of the milestone is reasonable in relation to the effort expended or the risk associated with achievement of the milestone, and (4) the milestone is at risk for both parties. If any of these conditions are not met, we defer the milestone payment and recognize it as revenue over the estimated period of performance under the contract.

RESEARCH AND DEVELOPMENT COSTS

Generally, research and development costs are expensed as incurred. Nonrefundable advance payments for goods or services that will be used or rendered for future research and development activities are deferred and amortized over the period that the goods are delivered or the related services are performed, subject to an assessment of recoverability. We make estimates of costs incurred in relation to external clinical research organizations, or CROs, and clinical site costs. We analyze the progress of clinical trials, including levels of patient enrollment, invoices received and contracted costs when evaluating the adequacy of the amount expensed and the related prepaid asset and accrued liability. Significant judgments and estimates must be made and used in determining the accrued balance and expense in any accounting period. We review and accrue CRO expenses and clinical trial study expenses based on work performed and rely upon estimates of those costs applicable to the stage of completion of a study. Accrued CRO costs are subject to revisions as such trials progress to completion. Revisions are charged to expense in the period in which the facts that give rise to the revision become known. With respect to clinical site costs, the financial terms of these agreements are subject to negotiation and vary from contract to contract. Payments under these contracts may be uneven, and depend on factors such as the achievement of certain events, the successful recruitment of patients, the completion of portions of the clinical trial or similar conditions. The objective of our policy is to match the recording of expenses in our financial statements to the actual services received and efforts expended. As such, expense accruals related to clinical site costs are recognized based on our estimate of the degree of completion of the event or events specified in the specific clinical study or trial contract.

Prepaid research and development in our consolidated balance sheet includes, among other things, certain fees related to development and manufacturing services. These development and manufacturing agreements often require payments in advance of services performed or goods received. Accordingly, as of December 31, 2015 and 2014, we recorded approximately $7.7 million and $5.8 million, respectively, in prepaid research and development related to such advance agreements.

INCOME TAXES

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, operating losses and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date. If the likelihood of realizing the deferred tax assets or liability is less than “more likely than not,” a valuation allowance is then created.

We, and our subsidiaries, file income tax returns in the U.S. Federal jurisdiction and in various states. We have tax net operating loss carryforwards that are subject to examination for a number of years beyond the year in which they were generated for tax purposes. Since a portion of these net operating loss carryforwards may be utilized in the future, many of these net operating loss carryforwards will remain subject to examination. We recognize interest and penalties related to uncertain income tax positions in income tax expense.

STOCK - BASED COMPENSATION

We recognize all share-based payments to employees and non-employee directors (as compensation for service) as noncash compensation expense in the consolidated financial statements based on the fair values of such payments. Stock-based compensation expense recognized each period is based on the value of the portion of share-based payment awards that is ultimately expected to vest during the period. Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.

For share-based payments to consultants and other third-parties (including related parties), noncash compensation expense is determined at the “measurement date.” The expense is recognized over the vesting period of the award. Until the measurement date is reached, the total amount of compensation expense remains uncertain. We record compensation expense based on the fair value of the award at the reporting date. The awards to consultants and other third-parties (including related parties) are then revalued, or the total compensation is recalculated based on the then current fair value, at each subsequent reporting date.

In addition, because some of the options, restricted stock and warrants issued to employees, consultants and other third-parties vest upon achievement of certain milestones, the total expense is uncertain. Compensation expense for such awards that vest upon the achievement of milestones is recognized when the achievement of such milestone becomes probable.

BASIC AND DILUTED NET LOSS PER COMMON SHARE

Basic net loss per common share is calculated by dividing net loss applicable to common shares by the weighted-average number of common shares outstanding for the period. Diluted net loss per common share is the same as basic net loss per common share, since potentially dilutive securities from stock options, stock warrants and convertible preferred stock would have an antidilutive effect either because the Company incurred a net loss during the period presented or because such potentially dilutive securities were out of the money and the Company realized net income during the period presented. The amounts of potentially dilutive securities excluded from the calculation were 7,064,396, 8,890,796 and 10,618,584 at December 31, 2015, 2014 and 2013, respectively. During the years ended December 31, 2015, 2014 and 2013 the Company incurred a net loss, therefore, all of the dilutive securities are excluded from the computation of diluted loss per share.

LONG-LIVED ASSETS AND GOODWILL

Long-lived assets are reviewed for an impairment loss when circumstances indicate that the carrying value of long-lived tangible and intangible assets with finite lives may not be recoverable. Management’s policy in determining whether an impairment indicator exists, a triggering event, comprises measurable operating performance criteria as well as qualitative measures. If an analysis is necessitated by the occurrence of a triggering event, we make certain assumptions in determining the impairment amount. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized.

Goodwill is reviewed for impairment annually, or when events arise that could indicate that an impairment exists. We test for goodwill impairment using a two-step process. The first step compares the fair value of the reporting unit with the unit's carrying value, including goodwill. When the carrying value of the reporting unit is greater than fair value, the unit’s goodwill may be impaired, and the second step must be completed to measure the amount of the goodwill impairment charge, if any. In the second step, the implied fair value of the reporting unit’s goodwill is compared with the carrying amount of the unit’s goodwill. If the carrying amount is greater than the implied fair value, the carrying value of the goodwill must be written down to its implied fair value. We will continue to perform impairment tests annually, at December 31, and whenever events or changes in circumstances suggest that the carrying value of an asset may not be recoverable.

CASH AND CASH EQUIVALENTS

12 Months Ended

Dec. 31, 2015

Cash and Cash Equivalents [Abstract]

Cash and Cash Equivalents Disclosure [Text Block]

NOTE 2 – CASH AND CASH EQUIVALENTS

The following tables summarize our cash and cash equivalents at December 31, 2015 and December 31, 2014:

	December 31, 2015		December 31, 2014

Money market funds	$	8,265,583	$	12,364,537
Checking and bank deposits		46,795,746		43,349,247
Total	$	55,061,329	$	55,713,784

- Definition

The entire disclosure for cash and cash equivalent footnotes, which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify.

+ References + Details

INVESTMENT SECURITIES

12 Months Ended

Dec. 31, 2015

Investments, Debt and Equity Securities [Abstract]

Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]

NOTE 3 – INVESTMENT SECURITIES

We record our investments as held-to-maturity. Held-to-maturity investments are recorded at amortized cost.

The following tables summarize our investment securities at December 31, 2015 and 2014:

	December 31, 2015
	Amortized cost, as adjusted		Gross unrealized holding gains		Gross unrealized holding losses		Estimated fair value
Short-term investments:
Obligations of domestic governmental agencies (maturing between January 2016 and December 2016) (held-to-maturity)	$	22,166,512	$	—	$	22,822	$	22,143,690

Long-term investments:
Obligations of domestic governmental agencies (maturing between January 2017 and December 2017) (held-to-maturity)		25,003,032		—		85,846		24,917,186
Total short-term and long-term investment securities	$	47,169,544	$	—	$	108,668	$	47,060,876

	December 31, 2014
	Amortized cost, as adjusted		Gross unrealized holding gains		Gross unrealized holding losses		Estimated fair value
Short-term investments:
Obligations of domestic governmental agencies (maturing between January 2015 and December 2015) (held-to-maturity)	$	23,062,034	$	922	$	5,806	$	23,057,150
Total short-term investment securities	$	23,062,034	$	922	$	5,806	$	23,057,150

- Definition

The entire disclosure for investments in certain debt and equity securities.

+ References + Details

FAIR VALUE MEASUREMENTS

12 Months Ended

Dec. 31, 2015

Fair Value Disclosures [Abstract]

Fair Value Disclosures [Text Block]

NOTE 4 – FAIR VALUE MEASUREMENTS

We measure certain financial assets and liabilities at fair value on a recurring basis in the financial statements. The fair value hierarchy ranks the quality and reliability of inputs, or assumptions, used in the determination of fair value and requires financial assets and liabilities carried at fair value to be classified and disclosed in one of the following three categories:

Level 1 – quoted prices in active markets for identical assets and liabilities;

Level 2 – inputs other than Level 1 quoted prices that are directly or indirectly observable; and

Level 3 – unobservable inputs that are not corroborated by market data.

As of December 31, 2015 and 2014, the fair values of cash and cash equivalents, restricted cash, and notes and interest payable, current portion approximate their carrying value.

At the time of our merger (we were then known as Manhattan Pharmaceuticals, Inc. (“Manhattan”)) with Ariston Pharmaceuticals, Inc. (“Ariston”) in March 2010, Ariston issued $15.5 million of five-year 5% notes payable (the “5% Notes”) in satisfaction of several note payable issuances. The 5% Notes and accrued and unpaid interest thereon are convertible at the option of the holder into common stock at the conversion price of $1,125 per share. Ariston agreed to make quarterly payments on the 5% Notes equal to 50% of the net product cash flow received from the exploitation or commercialization of Ariston’s product candidates, AST-726 and AST-915. We have no obligations under the 5% Notes aside from a) 50% of the net product cash flows from Ariston’s product candidates, if any, payable to noteholders; and b) the conversion feature, discussed above.

The cumulative liability including accrued and unpaid interest of the 5% Notes was approximately $19.9 million at December 31, 2015 and $19.5 million at December 31, 2014. No payments have been made on the 5% Notes as of December 31, 2015.

In December 2011, we elected the fair value option for valuing the 5% Notes. The fair value option was elected in order to reflect in our financial statements the assumptions that market participants use in evaluating these financial instruments.

As of December 31, 2013, as a result of expiring intellectual property rights and other factors, it was determined that net product cash flows from AST-726 were unlikely. As we have no other obligations under the 5% Notes aside from the net product cash flows and the conversion feature, the conversion feature was used to estimate the 5% Notes’ fair value as of December 31, 2015 and 2014. The assumptions, assessments and projections of future revenues are subject to uncertainties, difficult to predict, and require significant judgment. The use of different assumptions, applying different judgment to inherently subjective matters and changes in future market conditions could result in significantly different estimates of fair value and the differences could be material to our consolidated financial statements.

The following tables provide the fair value measurements of applicable financial liabilities as of December 31, 2015 and 2014:

	Financial liabilities at fair value as of December 31, 2015
	Level 1		Level 2		Level 3		Total

5% Notes	$	—	$	—	$	211,549	$	211,549
Totals	$	—	$	—	$	211,549	$	211,549

	Financial liabilities at fair value as of December 31, 2014
	Level 1		Level 2		Level 3		Total

5% Notes	$	—	$	—	$	275,190	$	275,190
Totals	$	—	$	—	$	275,190	$	275,190

The Level 3 amounts above represent the fair value of the 5% Notes and related accrued interest.

The following table summarizes the changes in Level 3 instruments for the years ended December 31, 2014 and 2015:

Balance at January 1, 2014	$	64,529
Interest accrued on face value of 5% Notes		930,701
Change in fair value of Level 3 liabilities		(720,040)
Balance at December 31, 2014		275,190
Interest accrued on face value of 5% Notes		972,736
Conversion of 5% Notes		(6,924)
Change in fair value of Level 3 liabilities		(1,029,453)
Balance at December 31, 2015	$	211,549

The change in the fair value of the Level 3 liabilities is reported in other (income) expense in the accompanying consolidated statements of operations.

Nonrecurring Fair Value Measurements

There were no nonrecurring fair value measurements during the year ended December 31, 2015. The following table summarizes the assets measured at fair value on a nonrecurring basis as of December 31, 2013:

	Fair value measurements as of December 31, 2013
	Level 1		Level 2		Level 3		Total impairment charge for the year ended December 31, 2013
Assets:
In-process research and development	$	—	$	—	$	—	$	(2,797,600)
Total	$	—	$	—	$	—	$	(2,797,600)

As of December 31, 2013, as a result of expiring intellectual property rights, uncertain regulatory pathways, and market changes affecting the commercial potential for the Ariston in-process research and development asset (AST-726), we determined that the asset's carrying value was no longer recoverable. Accordingly, during the year ended December 31, 2013, we recorded a non-cash impairment charge of $2,797,600, which was recorded as impairment of in-process research and development in our consolidated statements of operations. The fair value of this asset was determined to be zero primarily as a result of the expiring intellectual property rights surrounding the asset. This fair value measurement technique is based on significant inputs not observable in the market and thus represents a Level 3 measurement within the fair value hierarchy.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

STOCKHOLDERS' EQUITY

12 Months Ended

Dec. 31, 2015

Stockholders' Equity Note [Abstract]

Shareholders Equity and Share-based Payments [Text Block]

NOTE 5 – STOCKHOLDERS’ EQUITY

Preferred Stock

Our amended and restated certificate of incorporation authorizes the issuance of up to 10,000,000 shares of preferred stock, $0.001 par value, with rights senior to those of our common stock, issuable in one or more series. Upon issuance, the Company can determine the rights, preferences, privileges and restrictions thereof. These rights, preferences and privileges could include dividend rights, conversion rights, voting rights, terms of redemption, liquidation preferences, sinking fund terms and the number of shares constituting any series or the designation of such series, any or all of which may be greater than the rights of common stock.

Stockholder Rights Plan

On July 18, 2014, we adopted a stockholder rights plan. The stockholder rights plan is embodied in the Stockholder Protection Rights Agreement dated as of July 18, 2014 (the “Rights Agreement”), between us and American Stock Transfer & Trust Company, LLC, as rights agent (the “Rights Agent”).

Accordingly, the Board of Directors declared a distribution of one right (a “Right”) for each outstanding share of common stock, to stockholders of record at the close of business on July 28, 2014, for each share of common stock issued (including shares distributed from treasury) by us thereafter and prior to the Separation Time (as defined in the Rights Agreement), and for certain shares of common stock issued after the Separation Time. Following the Separation Time, each Right entitles the registered holder to purchase from us one one-thousandth (1/1,000) of a share of Series A Junior Participating Preferred Stock, par value $0.001 per share (the "Preferred Stock"), at a purchase price of $100.00 (the "Exercise Price"), subject to adjustment. The description and terms of the Rights are set forth in the Rights Agreement. Each one one-thousandth of a share of Preferred Stock has substantially the same rights as one share of common stock. Subject to the terms and conditions of the Rights Agreement, Rights become exercisable ten days after the public announcement that a “Person” has become an “Acquiring Person” (as each such term is defined in the Rights Agreement). Any Rights held by an Acquiring Person are void and may not be exercised.

If a Person becomes an Acquiring Person, all holders of Rights, except the Acquiring Person, may purchase at the Right’s then-current exercise price, common stock having a market value equal to twice the exercise price. Moreover, at any time after a Person becomes an Acquiring Person (unless such Person acquires 50 percent or more of our common stock then outstanding, as more fully described in the Rights Agreement), the Board of Directors may exchange all (but not less than all) of the then outstanding Rights (other than rights owned by such Person, which would have become void) for shares of common stock at an exchange ratio of one share of common stock per Right, appropriately adjusted in order to protect the interests of holders of Rights.

The Rights Agreement was approved by our Board of Directors on July 18, 2014. The Rights will expire at the close of business on its ten year anniversary, unless earlier exchanged or terminated by us.

Common Stock

Our amended and restated certificate of incorporation authorizes the issuance of up to 150,000,000 shares of $0.001 par value common stock. At the annual shareholder meeting on June 6, 2014, an amendment to the Company's Certificate of Incorporation to decrease its authorized share capital by 350,000,000 shares from 500,000,000 to 150,000,000 was approved.

On July 18, 2013, we announced the pricing of an underwritten public offering of 5,700,000 shares of our common stock at a price of $6.15 per share for gross proceeds of approximately $35 million. We also granted to the underwriters a 30-day option to acquire an additional 855,000 shares to cover overallotments in connection with the offering. Total net proceeds from this offering, including the overallotment, were approximately $37.6 million, net of underwriting discounts and offering expenses of approximately $2.7 million. The shares were sold under a shelf registration statement on Form S-3 (File No. 333-189015) that was previously filed and declared effective by the SEC on June 17, 2013.

On March 11, 2014, we announced the pricing of an underwritten sale of 2,702,809 shares of our common stock at a price of $6.71 per share for gross proceeds of approximately $18.1 million. Net proceeds from this offering were approximately $16.8 million, net of underwriting discounts and offering expenses of approximately $1.3 million. The shares were sold under a shelf registration statement on Form S-3 (File No. 333-189015) that was previously filed and declared effective by the SEC on June 17, 2013.

On June 21, 2013, we entered into an At-the-Market Issuance Sales Agreement (the “2013 ATM”) with MLV & Co. LLC (“MLV”) under which we could issue and sell shares of our common stock, having an aggregate offering price of up to $50.0 million, from time to time through MLV, acting as the sales agent. Under the agreement we would pay MLV a commission rate of up to 3.0% of the gross proceeds from the sale of any shares of common stock sold through MLV.

During the year ended December 31, 2014, we sold a total of 4,850,055 shares of common stock under the 2013 ATM for aggregate total gross proceeds of approximately $50.0 million at an average selling price of $10.31 per share. Net proceeds were approximately $48.9 million after deducting commissions and other transactions costs.

In December 2014, we filed a shelf registration statement on Form S-3 (the “2015 S-3”), which was declared effective in January 2015. Under the 2015 S-3, the Company may sell up to a total of $250 million of its securities. In connection with the 2015 S-3, we amended our 2013 At-the-Market Issuance Sales Agreement with MLV (the “2015 ATM”) such that we may issue and sell additional shares of our common stock, having an aggregate offering price of up to $75.0 million, from time to time through MLV, acting as the sales agent. Under the 2015 ATM we pay MLV a commission rate of up to 3.0% of the gross proceeds from the sale of any shares of common stock sold through MLV.

During the year ended December 31, 2015, we sold a total of 4,094,498 shares of common stock under the 2015 ATM for aggregate total gross proceeds of approximately $68.2 million at an average selling price of $16.66 per share, resulting in net proceeds of approximately $67.0 million after deducting commissions and other transaction costs.

We currently have two shelf registration statements on Form S-3 filed and declared effective by the SEC (File No. 333-189015 and File No. 333-201339). After deducting shares already sold, approximately $248 million of common stock remains available for sale under these shelf registration statements. We may offer the securities under our shelf registration statements from time to time in response to market conditions or other circumstances if we believe such a plan is in the best interests of our stockholders. We believe that these shelf registration statements provide us with the flexibility to raise additional capital to finance our operations as needed.

Treasury Stock

As of December 31, 2015 and 2014, 41,309 shares of common stock are being held in Treasury, at a cost of approximately $234,000, representing the fair market value on the date the shares were surrendered to the Company to satisfy employee tax obligations.

Equity Incentive Plans

In May 2012, we established the TG Therapeutics, Inc. Amended and Restated 2012 Incentive Plan (“2012 Incentive Plan”). Under the 2012 Incentive Plan, our compensation committee of board of directors is authorized to grant stock-based awards to directors, consultants, employees and officers. The 2012 Incentive Plan authorizes grants to purchase up to 6,000,000 shares of authorized but unissued common stock.

An amendment to the 2012 Incentive Plan was approved by stockholders in June 2015. Pursuant to this amendment, 6,000,000 shares were added to the 2012 Incentive Plan. As of December 31, 2015, no options were outstanding and up to an additional 4,164,631 shares may be issued under the 2012 Incentive Plan.

Stock Options

The following table summarizes stock option activity for the years ended December 31, 2015, 2014 and 2013:

	Number of shares		Weighted- average exercise price		Weighted- average contractual term		Aggregate intrinsic value
					(in years)
Outstanding at January 1, 2013		46,904	$	61.08		9.44
Granted		—		—
Exercised		—		—
Forfeited		(313)		2,249.85
Expired		—		—
Outstanding at December 31, 2013		46,591		46.37		8.50	$	—
Granted		—		—
Exercised		(46,000)		4.40
Forfeited		—		—
Expired		(397)		4,457.57
Outstanding at December 31, 2014		194		971.70		3.50	$	—
Granted		—		—
Exercised		—		—
Forfeited		(152)		463.32
Expired		(42)		2,811.53
Outstanding at December 31, 2015		—	$	—		—	$	—

Exercisable at December 31, 2015		—	$	—		—	$	—

As of December 31, 2015, there are no unvested option awards and no unrecognized compensation cost related option awards.

Restricted Stock

Certain employees, directors and consultants have been awarded restricted stock. The restricted stock vesting consists of milestone and time-based vesting. The following table summarizes restricted share activity for the years ended December 31, 2015, 2014 and 2013:

	Number of Shares		Weighted Average Grant Date Fair Value
Outstanding at January 1, 2013		6,614,243	$	4.49
Granted		944,464		4.13
Vested		(523,750)		2.48
Forfeited		—		—
Outstanding at December 31, 2013		7,034,957		4.60
Granted		982,793		13.55
Vested		(1,616,749)		6.53
Forfeited		(1,000)		6.60
Outstanding at December 31, 2014		6,400,001		5.86
Granted		1,992,535		12.89
Vested		(1,001,455)		5.04
Forfeited		(31,166)		16.76
Outstanding at December 31, 2015		7,359,915	$	7.83

Total expense associated with restricted stock grants was $15,697,092, $20,726,512 and $5,146,743 during the years ended December 31, 2015, 2014 and 2013, respectively. As of December 31, 2015, there was approximately $22.9 million of total unrecognized compensation cost related to unvested time-based restricted stock, which is expected to be recognized over a weighted-average period of 2.2 years. This amount does not include, as of December 31, 2015, 411,172 shares of restricted stock outstanding which are milestone-based and vest upon certain corporate milestones; and 2,371,167 shares of restricted stock outstanding issued to non-employees. Milestone-based non-cash compensation expense will be measured and recorded if and when a milestone becomes probable. The expense for non-employee shares is determined at the “measurement date.” The expense is recognized over the vesting period of the award. Until the measurement date is reached, the total amount of compensation expense remains uncertain. We record compensation expense based on the fair value of the award at the reporting date.

Warrants

The following table summarizes warrant activity for the years ended December 31, 2015, 2014 and 2013:

	Warrants		Weighted- Average exercise price		Aggregate intrinsic value
Outstanding at January 1, 2013		6,781,007	$	1.58	$	14,563,539
Issued		—		—
Exercised		(1,018,068)		2.25
Expired		(43,992)		16.26
Outstanding at December 31, 2013		5,718,947		1.34	$	14,809,030
Issued		—		—
Exercised		(1,560,826)		2.28
Expired		(9,893)		20.74
Outstanding at December 31, 2014		4,148,228		0.94	$	61,792,184
Issued		—		—
Exercised		(2,950,115)		0.36
Expired		(11,364)		2.25
Outstanding at December 31, 2015		1,186,749	$	2.37	$	11,341,452

Stock-Based Compensation

The fair value of stock options granted is estimated at the date of grant using the Black-Scholes pricing model. The expected term of options granted is derived from historical data and the expected vesting period. Expected volatility is based on the historical volatility of our common stock. The risk-free interest rate is based on the U.S. Treasury yield for a period consistent with the expected term of the option in effect at the time of the grant. We have assumed no expected dividend yield, as dividends have never been paid to stock or option holders and will not be paid for the foreseeable future. The Company did not grant any stock options during the years ended December 31, 2015, 2014 and 2013.

The following table summarizes stock-based compensation expense information about stock options and restricted stock for the years ended December 31, 2015, 2014 and 2013:

	2015		2014		2013

Stock-based compensation expense associated with restricted stock	$	15,697,092	$	20,726,512	$	5,146,743
Stock-based compensation expense associated with stock options		—		378,780		56,405
	$	15,697,092	$	21,105,292	$	5,203,148

NOTES PAYABLE

12 Months Ended

Dec. 31, 2015

Debt Disclosure [Abstract]

Debt Disclosure [Text Block]

NOTE 6 – NOTES PAYABLE

The following is a summary of notes payable:

	December 31, 2015						December 31, 2014
	Current portion, net		Non- current portion, net		Total		Current portion, net		Non- current portion, net		Total
Convertible 5% Notes Payable	$	211,549	$	-	$	211,549	$	275,190	$	-	$	275,190
Totals	$	211,549	$	-	$	211,549	$	275,190	$	-	$	275,190

Convertible 5% Notes Payable

On March 8, 2010, Manhattan entered into an Agreement and Plan of Merger (the "Merger Agreement") by and among Manhattan, Ariston and Ariston Merger Corp., a Delaware corporation and wholly-owned subsidiary of Manhattan (the "Merger Sub"). Pursuant to the terms and conditions of the Merger Agreement, on March 8, 2010, the Merger Sub merged with and into Ariston (the "Merger"), with Ariston being the surviving corporation of the Merger. As a result of the Merger, Ariston became a wholly-owned subsidiary of Manhattan.

The 5% Notes and accrued and unpaid interest thereon are convertible at the option of the holder into common stock at the conversion price of $1,125 per share. Ariston agreed to make quarterly payments on the 5% Notes equal to 50% of the net product cash flow received from the exploitation or commercialization of Ariston’s product candidates, AST-726 and AST-915. We have no obligation under the 5% Notes aside from a) 50% of the net product cash flows from Ariston’s product candidates, if any, payable to noteholders; and b) the conversion feature, discussed above. Interest accrues monthly, is added to principal on an annual basis, every March 8, and is payable at maturity, which was March 8, 2015.

The cumulative liability including accrued and unpaid interest of these notes was approximately $19.9 million at December 31, 2015 and $19.5 million at December 31, 2014. No payments have been made on the 5% Notes as of December 31, 2015.

INCOME TAXES

12 Months Ended

Dec. 31, 2015

Income Tax Disclosure [Abstract]

Income Tax Disclosure [Text Block]

NOTE 7 – INCOME TAXES

We account for income taxes under the asset and liability method. Deferred tax assets and liabilities are determined based on differences between the financial reporting and tax basis of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is established when necessary to reduce deferred tax assets to the amount expected to be realized. In determining the need for a valuation allowance, management reviews both positive and negative evidence, including current and historical results of operations, future income projections and the overall prospects of our business. Based upon management's assessment of all available evidence, we believe that it is more-likely-than-not that the deferred tax assets will not be realizable, and therefore, a valuation allowance has been established. The valuation allowance for deferred tax assets was approximately $86,359,000, $69,084,000 and $46,283,000 as of December 31, 2015, 2014 and 2013, respectively.

As of December 31, 2015, we have U.S. net operating loss carryforwards (“NOLs”) of approximately $195,895,000. For income tax purposes, these NOLs will expire in various amounts through 2035. The Tax Reform Act of 1986 contains provisions which limit the ability to utilize net operating loss carryforwards in the case of certain events including significant changes in ownership interests. The Exchange Transaction with TG Bio may have resulted in a “change in ownership” as defined by IRC Section 382 of the Internal Revenue Code of 1986, as amended. Additionally, stock issuance activities may have resulted in a “change in ownership” as defined by IRC Section 382 of the Internal Revenue Code of 1986, as amended. Accordingly, a substantial portion of the Company’s NOLs above may be subject to annual limitations in reducing any future year’s taxable income.

The tax effects of temporary differences that give rise to significant portions of the deferred tax assets and deferred tax liabilities at December 31, 2015 and 2014 are presented below.

	2015		2014
Deferred tax assets (liabilities):
Net operating loss carryforwards	$	68,700,379	$	52,350,293
Research and development credit		4,962,298		3,358,934
Noncash compensation		12,087,968		12,417,815
Acquired in-process research and development		—		—
Foreign tax credit		—		—
Other		608,205		956,727
Deferred tax asset, excluding valuation allowance		86,358,850		69,083,769

Less valuation allowance		(86,358,850)		(69,083,769)
Net deferred tax assets	$	—	$	—

There was no current or deferred income tax expense for the year ended December 31, 2015. Income tax expense differed from amounts computed by applying the US Federal income tax rate of 34% to pretax loss as follows:

	For the year ended December 31,
	2015		2014		2013

Loss before income taxes, as reported in the consolidated statements of operations	$	(62,948,646)	$	(55,781,277)	$	(20,478,210)

Computed “expected” tax benefit	$	(21,402,540)	$	(18,965,634)	$	(6,962,592)

Increase (decrease) in income taxes resulting from:
Expected benefit from state and local taxes		(672,306)		(2,533,156)		(917,810)
Research and development credits		(1,603,364)		(1,092,767)		(250,000)
Other		566,310		35,459		43,026
Permanent difference related to contingent note payable		—		(244,814)		(1,924,558)
Impact of change in state tax rates on deferred taxes		5,836,819		—		—
Change in the balance of the valuation allowance for deferred tax assets		17,275,081		22,800,912		10,011,934
	$	—	$	—	$	—

We file income tax returns in the U.S. Federal and various state and local jurisdictions. With certain exceptions, the Company is no longer subject to U.S. Federal and state income tax examinations by tax authorities for years prior to 2011. However, NOLs and tax credits generated from those prior years could still be adjusted upon audit.

The Company recognizes interest and penalties to uncertain tax position in income tax expense in the statement of operations. There was no accrual for interest and penalties related to uncertain tax positions for 2015 and 2014. We do not believe that there will be a material change in our unrecognized tax positions over the next twelve months. All of the unrecognized tax benefits, if recognized, would be offset by the valuation allowance.

LICENSE AGREEMENTS

12 Months Ended

Dec. 31, 2015

License Agreement [Abstract]

License Agreement Disclosure [Text Block]

NOTE 8 – LICENSE AGREEMENTS

Anti-PD-L1 and anti-GITR

On March 3, 2015, we entered into a Global Collaboration Agreement (the “Collaboration”) with Checkpoint Therapeutics, Inc. (“Checkpoint”), a subsidiary of Fortress Biotech, Inc. (“Fortress”), a related party, for the development and commercialization of Checkpoint’s anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. Checkpoint retains the rights to develop and commercialize these antibodies in solid tumors.

Under the terms of the Collaboration, we made an up-front payment of $0.5 million, will make development and sales-based milestone payments up to an aggregate of $164 million, and will pay a tiered single digit royalty on net sales. The royalty term will terminate on a country by country basis upon the later of (i) ten years after the first commercial sale of any applicable licensed product in such country, or (ii) the expiration of the last-to-expire patent held by the Dana Farber Cancer Institute containing a valid claim to any licensed product in such country.

Michael Weiss, our Executive Chairman, Interim CEO and President is also the Executive Vice Chairman of Fortress and the Executive Chairman of Checkpoint (See Note 9).

TGR-1202

On September 22, 2014, we exercised our option to license the global rights to TGR-1202, thereby entering into an exclusive licensing agreement (the “TGR-1202 License”) with Rhizen Pharmaceuticals, SA (“Rhizen”) for the development and commercialization of TGR-1202. Prior to this, we had been jointly developing TGR-1202 in a 50:50 joint venture with Rhizen.

Under the terms of the TGR-1202 License, Rhizen received a $4.0 million cash payment and 371,530 shares of our common stock as an upfront license fee. With respect to TGR-1202, Rhizen will be eligible to receive regulatory filing, approval and sales-based milestone payments in the aggregate of approximately $175 million, a small portion of which will be payable on the first New Drug Application (NDA) filing and the remainder on approval in multiple jurisdictions for up to two oncology indications and one non-oncology indication and attaining certain sales milestones. In addition, if TGR-1202 is co-formulated with another drug to create a new product (a "New Product"), Rhizen will be eligible to receive similar regulatory approval and sales-based milestone payments for such New Product. Additionally, Rhizen will be entitled to tiered royalties on our future net sales of TGR-1202 and any New Product. In lieu of sales milestones and royalties on net sales, Rhizen shall also be eligible to participate in sublicensing revenue, if any, based on a percentage that decreases as a function of the number of patients treated in clinical trials following the exercise of the license option. Rhizen will retain global manufacturing rights to TGR-1202, provided that they are price competitive with alternative manufacturers.

In connection with the TGR-1202 License, we recognized $4.1 million of noncash research and development expense during the year ended December 31, 2014 related to the issuance of the above mentioned common stock. In addition, we recognized $4.0 million of other research and development expense during the year ended December 31, 2014 related to the cash milestone payment.

IRAK4

On June 23, 2014, we entered into an exclusive licensing agreement with Ligand Pharmaceuticals Incorporated ("Ligand") for the development and commercialization of Ligand's interleukin-1 receptor associated kinase-4 ("IRAK4") inhibitor technology, which currently is in preclinical development for potential use against certain cancers and autoimmune diseases. IRAK4 is a serine/threonine protein kinase that is a key downstream signaling component of the interleukin-1 receptor and multiple toll-like receptors.

Under the terms of the license agreement, Ligand received 125,000 shares of our common stock as an upfront license fee. Ligand will also be eligible to receive maximum potential milestone payments of approximately $207 million upon the achievement of specific clinical, regulatory and commercial milestone events. Additionally, Ligand will be entitled to royalties on our future net sales of licensed products containing IRAK4 inhibitors. The basic royalty rate for licensed products covered by Ligand's issued patents will be 6% for annual sales of up to $1 billion and 9.5% for annual sales in excess of that threshold.

In connection with the license agreement, we recognized $1,211,250 of noncash research and development expense during the year ended December 31, 2014 in connection with the issuance of the above mentioned common stock.

Additionally, Opus Point Partners, LLC, who identified the opportunity and advised us on the transaction, will also be entitled to receive a 1% royalty for annual sales of up to $1 billion. Michael S. Weiss, our Executive Chairman and Interim Chief Executive Officer, is a Managing Member of Opus Point Partners, LLC.

TG-1101

In November 2012, we entered into an exclusive (within the territory) sublicense agreement with Ildong relating to the development and commercialization of TG-1101 in South Korea and Southeast Asia. Under the terms of the sublicense agreement, Ildong has been granted a royalty bearing, exclusive right, including the right to grant sublicenses, to develop and commercialize TG-1101 in South Korea, Taiwan, Singapore, Indonesia, Malaysia, Thailand, Philippines, Vietnam, and Myanmar.

An upfront payment of $2.0 million, which was received in December 2012, net of $0.3 million of income tax withholdings, is being recognized as license revenue on a straight-line basis over the life of the agreement, which is through the expiration of the last licensed patent right or 15 years after the first commercial sale of a product in such country, unless the agreement is earlier terminated, and represents the estimated period over which we will have certain ongoing responsibilities under the sublicense agreement. We recorded license revenue of approximately $152,000 for each of the years ended December 31, 2015, 2014 and 2013, and, at December 31, 2015, 2014 and 2013, have deferred revenue of approximately $1,524,000, $1,676,000 and $1,829,000, respectively, associated with this $2,000,000 payment (approximately $152,000 of which has been classified in current liabilities at December 31, 2015).

We may receive up to an additional $5.0 million in payments upon the achievement of pre-specified milestones. In addition, upon commercialization, Ildong will make royalty payments to us on net sales of TG-1101 in the sublicense territory.

RELATED PARTY TRANSACTIONS

12 Months Ended

Dec. 31, 2015

NOTE 9 – RELATED PARTY TRANSACTIONS

LFB Biotechnologies

On January 30, 2012, we entered into an exclusive license agreement with LFB Biotechnologies, GTC Biotherapeutics and LFB/GTC LLC, all wholly-owned subsidiaries of LFB Group, relating to the development of ublituximab (the “LFB License Agreement”). In connection with the LFB License Agreement, LFB Group was issued 5,000,000 shares of common stock, and a warrant to purchase 2,500,000 shares of common stock at a purchase price of $0.001 per share. In addition, on November 9, 2012, we nominated Dr. Yann Echelard to our Board of Directors as LFB Group’s nominee. LFB Group maintains the right to nominate a board member until such time as LFB Group owns less than 10% of the outstanding common stock.

In connection with the LFB License Agreement, LFB Group maintained the right to purchase at least $750,000 in additional shares of common stock at a purchase price per share as defined in a November 2012 securities exchange agreement. Accordingly, in February 2015, LFB Group purchased 114,855 shares of our common stock at a price of $6.53 per share for net proceeds of $750,000. In May 2015, LFB Group exercised its warrant to purchase 2,500,000 shares of common stock at a purchase price of $0.001 per share.

Under the terms of the LFB License Agreement, we utilize LFB Group for certain development and manufacturing services. We incurred approximately $9,300,000, $5,200,000 and $6,300,000 in expenses for such services during the years ended December 31, 2015, 2014 and 2013, respectively, which have been included in other research and development expenses in the accompanying consolidated statements of operations. As of December 31, 2015, and 2014, we had approximately $2.1 million and $0.1 million, respectively, recorded in accounts payable related to the LFB License Agreement. In conjunction with the development and manufacturing services discussed above, certain agreements between us and LFB Group require payments in advance of services performed or goods delivered. Accordingly, as of December 31, 2015 and 2014, we recorded $3.0 million and $1.9 million, respectively, in prepaid research and development for such advance payments.

Other Parties

In March 2014, we entered into a shared services agreement (the “Opus Shared Services Agreement”) with Opus Point Partners Management, LLC (“Opus”) in which the parties agreed to share a rented facility and costs for certain other services. Michael S. Weiss, our Executive Chairman and Interim Chief Executive Officer, is a Managing Member of Opus. During the years ended December 31, 2015 and 2014, we incurred expenses of approximately $0.3 million and $0.1 million, respectively, principally for rent, related to this Opus Shared Services Agreement. As of December 31, 2015 and 2014, we had approximately $0.1 million and $0.02 million, respectively, recorded in accounts payable related to this Opus Shared Services Agreement.

As discussed in Note 8 above, in connection with the licensing agreement with Ligand, Opus Point Partners, LLC, who identified the opportunity and advised us on the transaction, will be entitled to receive a 1% royalty for annual sales of up to $1 billion.

As discussed in Note 8 above, with regard to the Collaboration with Checkpoint, our Executive Chairman and Interim Chief Executive Officer is also the Executive Vice Chairman of Fortress and the Executive Chairman of Checkpoint. In addition, Mr. Weiss holds equity interests in TG, Fortress and Checkpoint.

On October 3, 2014, we entered into a Desk Space Agreement (the “Desk Agreement”) with Fortress, to occupy approximately 40% of the New York City office space recently leased by Fortress. This Desk Agreement requires us to pay our respective share of the average annual rent and other costs of the 15 year lease. We approximate an average annual rental obligation of $1.1 million under the Desk Agreement. Fortress does not expect to take possession of the space until early 2016.

In connection with the Desk Agreement, we paid approximately $0.1 million in advance rent, which is recorded in other current assets in the accompanying consolidated balance sheets as of December 31, 2015 and December 31, 2014. During the year ended December 31, 2015, we incurred expenses of approximately $0.2 million, principally for our share of project management services, related to this agreement, of which $0.1 million was recorded in accounts payable. Also in connection with this lease, in October 2014 we pledged $0.6 million to secure a line of credit as a security deposit for the Desk Agreement, which has been recorded as Restricted Cash in the accompanying consolidated balance sheets.

In July 2015, we entered into a Shared Services Agreement (the “Shared Services Agreement”) with Fortress to share the cost of certain services such as facilities use, shared personnel costs and other shared overhead and administrative costs. This Shared Services Agreement requires us to pay our respective share of services utilized. In connection with the Shared Services Agreement, we incurred expenses of approximately $0.1 million for shared services as of December 31, 2015, which included only costs for shared personnel costs.

On September 1, 2015, we paid $25,000 to Checkpoint as an option fee for the exclusive right to enter into a collaboration for certain additional compounds licensed by Checkpoint. The option has not been exercised as of December 31, 2015. As of December 31, 2015, we had approximately $0.3 million recorded in accounts payable related to a sponsored research agreement.

For the year ended December 31, 2015, we incurred expenses of approximately $23,000 to AOI Communications, L.P. for manuscript services related to TG-1101. Our Executive Chairman and Interim Chief Executive Officer is the owner of AOI Communications, L.P.

- Definition

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References + Details

COMMITMENTS AND CONTINGENCIES

12 Months Ended

Dec. 31, 2015

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies Disclosure [Text Block]

NOTE 10 – COMMITMENTS AND CONTINGENCIES

As of December 31, 2015, we have known contractual obligations, commitments and contingencies of $16.3 million related to our operating lease obligations.

(in thousands)	Payment due by period
	Total		Less than 1 year		1-3 years		3-5 years		More than 5 years
Contractual obligations
Operating leases	$	16,335	$	128	$	1,947	$	1,992	$	12,268
Total	$	16,335	$	128	$	1,947	$	1,992	$	12,268

Leases

On October 3, 2014, we entered into a Desk Agreement with Fortress, to occupy approximately 40% of the New York City office space recently leased by Fortress. This Desk Agreement requires us to pay our respective share of the average annual rent and other costs of the 15 year lease. We approximate an average annual rental obligation of $1.1 million under the Desk Agreement. Fortress does not expect to take possession of the space until early 2016.

Total rental expense was approximately $0.3 million, $0.1 million and $0.01 million for the years ended December 31, 2015, 2014 and 2013, respectively.

Future minimum lease commitments as of December 31, 2015, in the aggregate total approximately $16.3 million through December 31, 2031. The preceding table shows future minimum lease commitments, which include our office leases in New York, North Carolina and Tennessee, by period as of December 31, 2015.

QUARTERLY FINANCIAL INFORMATION

12 Months Ended

Dec. 31, 2015

Disclosure Text Block [Abstract]

Quarterly Financial Information [Text Block]

NOTE 11 – QUARTERLY FINANCIAL INFORMATION (UNAUDITED)

	3 Months Ended
	March 31, 2015		June 30, 2015		September 30, 2015		December 31, 2015

License revenue	$	38,095	$	38,095	$	38,096	$	38,095

Total costs and expenses		14,640,946		17,149,675		13,863,680		17,678,096

Net loss	$	(14,577,735)	$	(17,103,183)	$	(13,655,916)	$	(17,611,812)

Basic and diluted net loss per common share	$	(0.35)	$	(0.38)	$	(0.28)	$	(0.37)

	3 Months Ended
	March 31, 2014		June 30, 2014		September 30, 2014		December 31, 2014

License revenue	$	38,095	$	38,095	$	38,096	$	38,095

Total costs and expenses		7,643,220		11,993,592		17,477,442		18,759,219

Net loss	$	(7,547,249)	$	(11,986,430)	$	(17,451,169)	$	(18,796,429)

Basic and diluted net loss per common share	$	(0.25)	$	(0.36)	$	(0.51)	$	(0.48)